Twitter Beğeni Hilesi

In the redhot gene insertion field, most new startups are focused on the editing enzymes that integrate DNA. But Floris Engelhardt, cofounder and CEO of Kano Therapeutics, is working on improving the DNA payload itself. Read more in my exclusive for Endpoints News: endpts.com/exclusive-mit-…

FDA delays approval decision on Humacyte's lab-grown blood vessels. Read more in my story for Endpoints News: endpts.com/fda-delays-app…

When Prolific Machines told me they were using #optogenetics to manufacture biologic drugs, my ears perked up. How would that work? Details are still a little fuzzy, but they've got a Gates Foundation grant to help them do it. My exclusive for Endpoints News: endpts.com/exclusive-gate…

Today Eli Lilly and Company opened its long-awaited research center in Boston with a focus on genetic medicines. CSO Dan Skovronsky said genetic medicines now make up one-third of Lilly's pipeline. Read more in my story for Endpoints News: endpts.com/lilly-opens-hu…

Congrats Jason Mast! So well deserved!

Last week Eli Lilly and Company opened its new genetic medicines-focused R&D center in Boston. I sat down with Dan Skovronsky and Andrew Adams to discuss their ambitions for DNA and RNA based drugs, and how they’re not just for rare diseases. More in Endpoints News: endpts.com/qa-lillys-top-…

It's tough out there for preclinical gene editing companies. Tome Biosciences, a leader in the gene insertion field, couldn't raise new funds or find a partner to continue its lab work. CEO Rahul Kakkar opened up about the dire situation in an interview: endpts.com/gene-insertion…

IDO1 inhibitors, once-promising cancer drugs designed to ramp up the immune system, appear to protect mice from #Alzheimers by restoring astrocyte metabolism and even slowing amyloid and tau pathology. Read more in my story for Endpoints News: endpts.com/once-promising…

I talked to Jacob Rubens about how his startup Quotient Therapeutics is looking for chance genetic mutations that push or pull cells to and from disease, the startup's vast ambitions, and its new heart and kidney disease partnership with Pfizer. My story in Endpoints News: endpts.com/pfizer-partner…

Here's an interesting use of AI in drug design: making compact proteins. ZipBio is shaving off the unimportant parts of proteins and using generative AI to fill in a backbone that holds the molecule together. Read more in my exclusive for Endpoints News: endpts.com/exclusive-zipb…

I talked to Astellas Pharma CEO Naoki Okamura about the company’s post-Xtandi plans, its M&A strategy, its new focus on protein degraders, its longstanding commitment to cell and gene therapy, and the importance of planting roots in Boston. Endpoints News: endpts.com/astellas-ceo-t…

Exclusive for Endpoints News: A male contraceptive called NES/T was >99% efficacious at preventing pregnancies in a Phase 2 trial, according to Contraline CEO Kevin Eisenfrats, whose startup has just licesned the drug from the Population Council to do a Phase 3 study. endpts.com/exclusive-a-ma…

Seres' microbiome therapy, made from 16 cultivated strains of bacteria, reduces infections in stem cell transplant patients in a Phase 1 study of 34 patients. But the next steps for the cash-strapped company are unclear. Read more in my story for Endpoints News: endpts.com/seres-microbio…

#ESMO24: Retrospective study suggests Covid mRNA vaccines may boost checkpoint inhibitor efficacy, doubling 3-year overall survival in advanced lung cancer patients and raising questions about the importance of cancer vaccine personalization. Endpoints News: endpts.com/esmo24-in-surp…

A promising new approach that could slow, stop or prevent nerves from dying in diseases like ALS may get its first test in patients next year. Nura Bio raised $68M for clinical tests of its SARM1 inhibitor to stop nerve degeneration. Read more in Endpoints News endpts.com/nura-bio-raise…

Stem cell startup GC Therapeutics, spun out of George Church’s lab, raises $75M for its transcription factor screening tech to quickly turn iPSCs into any adult cell, as well "SuperCells" enhanced for fighting disease. Read more in my story for Endpoints News endpts.com/stem-cell-star…

2024 might be remembered as the year GLP-1 drugs exploded on the market, but the science behind them dates back decades. On Thursday, the Lasker Foundation honored 3 scientists whose work paved the way to the obesity drug boom. Read more in Endpoints News endpts.com/lasker-award-g…